End with a summary. "In conclusion, JUQ-578 offers [key benefit] and is suitable for [target audience]. I [recommend/do not recommend] it based on [reason]."
| Patent | Publication | Key Claims | |--------|-------------|------------| | US 11,925,487 (2024) | WO 2024/108765 | Core pyrido‑pyrimidine scaffold, fluorobenzyl substitution, morpholine linker; method of use for NLRP3 inhibition. | | US 12,101,023 (2025) | US 2025/041215 | Crystalline forms A–D of JUQ‑578; improved bioavailability formulations. | | US 12,189,842 (2025) | US 2025/067890 | Combination therapy with GLP‑1 agonists for T2D; synergistic reduction of IL‑1β. |
End with a summary. "In conclusion, JUQ-578 offers [key benefit] and is suitable for [target audience]. I [recommend/do not recommend] it based on [reason]."
| Patent | Publication | Key Claims | |--------|-------------|------------| | US 11,925,487 (2024) | WO 2024/108765 | Core pyrido‑pyrimidine scaffold, fluorobenzyl substitution, morpholine linker; method of use for NLRP3 inhibition. | | US 12,101,023 (2025) | US 2025/041215 | Crystalline forms A–D of JUQ‑578; improved bioavailability formulations. | | US 12,189,842 (2025) | US 2025/067890 | Combination therapy with GLP‑1 agonists for T2D; synergistic reduction of IL‑1β. | JUQ-578